Sun Pharma commissions Dadra plant
30 Mar 2002
Chennai: The Rs 621-crore turnover Sun Pharma, India's largest speciality pharmaceutical company, has commenced commercial production at its new formulation plant in Dadra. This is the company's fourth formulation plant and the eighth production site. Sun Pharma has invested about Rs 25 crore for the plant.
The new plant, situated in the union territory of Dadra, is spread over a five-acre site with a built-up area of 1,20,000 sq ft and has an installed capacity of 2,400 million tablets per annum. The plant has been designed and built to comply with international regulatory requirements, like the UKMCA, the USFDA and the South African MCC. The Dadra plant has facilities for the manufacture of solid oral dosage forms (tablets and capsules) and dry powder inhalers.
Says Sun Pharma chairman and managing director Dilip Shanghvi: "This plant considerably enhances our capacity to address the international market for dosage forms and will meet demand surges from the domestic market."
The new plant, situated in the union territory of Dadra, is spread over a five-acre site with a built-up area of 1,20,000 sq ft and has an installed capacity of 2,400 million tablets per annum. The plant has been designed and built to comply with international regulatory requirements, like the UKMCA, the USFDA and the South African MCC. The Dadra plant has facilities for the manufacture of solid oral dosage forms (tablets and capsules) and dry powder inhalers.Says Sun Pharma chairman and managing director Dilip Shanghvi: "This plant considerably enhances our capacity to address the international market for dosage forms and will meet demand surges from the domestic market."